Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA4 | P22748 | 1/20 | 0.43 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.34 |
| ▸ | FEN1 | P39748 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25354521 | 0.85 | CA2 (0.33) | CA2CA4 | |
| SCHEMBL25356919 | 0.76 | HSD17B10 (0.36) | HSD17B10ALOX15TSHR | |
| SCHEMBL30454209 | 0.76 | HSD17B10 (0.36) | HSD17B10ALOX15TSHR | |
| SCHEMBL23088126 | 0.76 | CA2 (0.35) | CA2CA4ALOX5APFEN1HSD17B10 | |
| SCHEMBL25353709 | 0.74 | PDXK (0.36) | HSD17B10 | |
| SCHEMBL30453142 | 0.72 | TSHR (0.38) | HSD17B10TSHR | |
| SCHEMBL25356115 | 0.72 | TSHR (0.38) | HSD17B10TSHR | |
| SCHEMBL25354537 | 0.72 | — | — | |
| SCHEMBL30454331 | 0.72 | — | — | |
| SCHEMBL5942259 | 0.71 | CA2 (0.34) | CA2CA4HSD17B10TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250114374-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. | 2025-04-10 | — | — | US | disclosed |
| WO-2023122000-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. (US) | 2023-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250114374-A1 | BCL-2 INHIBITORS | BCL2, BCL2L1, BCL2L10 | CA2 2656/4885CA4 2534/4885ALOX5AP 2053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.